Evaluation of the therapeutic and protective properties of agomelatine in an experimental rat spinal cord injury (SCI) model
DOI:
https://doi.org/10.5281/zenodo.18099856Keywords:
Spinal cord injury, agomelatin, laminectomy, ratsAbstract
The aim of this study was to investigate the effect of agomelatin treatment after spinal cord injury. A total of 24 male Sprague Dawley rats were used in the study, with 6 animals in each group. The groups consisted of 4 subgroups: control, spinal cord injury (SI), spinal cord injury-agomelatin (SI-A), and agomelatin (A). The control group underwent laminectomy only at the T7-T9 level. In the SI group, following T7-T9 laminectomy, the dura was left intact and the spinal cord was compressed with the Tator and Rivlin clip method for one minute. In the SI-A group, following T7-T9 laminectomy, the dura was left intact and the spinal cord was compressed with the Tator and Rivlin clip method for one minute, followed by seven days of 20 mg/kg oral agomelatin treatment. In the A group, laminectomy was performed at T7-T9 followed by seven days of 20 mg/kg oral agomelatin treatment. On the seventh day, the surgical wound was reopened, and the injured spinal cord was carefully removed. Histopathological examination of the spinal cord samples was performed. The control group showed a normal histological appearance. In the SI group, an increase in hemorrhage areas was observed in hematoxylin-eosin staining. In the SI-A group, a decrease in hemorrhage areas was observed compared to the SI group. No abnormal structures were found in the A group. In conclusion, agomelatin administration after spinal cord injury has shown a therapeutic effect in spinal cord injury.
References
1. Lee JY, Kim HS, Choi HY, Oh TH, Ju BG, Yune TY. Valproic acid attenuates blood-spinal cord barrier disruption by inhibiting matrix metalloprotease-9 activity and improves functional recovery after spinal cord injury. J Neurochem. 2012;121(5):818-829. doi:10.1111/J.1471-4159.2012.07731.X;REQUESTEDJOURNAL:JOURNAL:14714159;ISSUE:ISSUE:DOI
2. Zhou Y, Wu Y, Liu Y, et al. The cross-talk between autophagy and endoplasmic reticulum stress in blood-spinal cord barrier disruption after spinal cord injury. Oncotarget. 2017;8(1):1688-1702. doi:10.18632/oncotarget.13777
3. Figley SA, Khosravi R, Legasto JM, Tseng YF, Fehlings MG. Characterization of Vascular Disruption and Blood–Spinal Cord Barrier Permeability following Traumatic Spinal Cord Injury. J Neurotrauma. 2014;31(6):541-552. doi:10.1089/neu.2013.3034
4. Lebedev S V., Karasev A V., Chekhonin VP, et al. Study of the Efficiency of Transplantation of Human Neural Stem Cells to Rats with Spinal Trauma: the Use of Functional Load Tests and BBB Test. Bull Exp Biol Med. 2010;149(3):377-382. doi:10.1007/s10517-010-0950-z
5. De Berardis D, Fornaro M, Serroni N, et al. Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression. Int J Mol Sci. 2015;16(1):1111-1130. doi:10.3390/ijms16011111
6. Gahr M. Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks. Curr Neuropharmacol. 2014;12(5):387-398. doi:10.2174/1570159X12999140619122914
7. Callegari I, Mattei C, Benassi F, et al. Agomelatine Improves Apathy in Frontotemporal Dementia. Neurodegener Dis. 2016;16(5-6):352-356. doi:10.1159/000445873
8. Savino R, Polito AN, Marsala G, et al. Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders. Brain Sci. 2023;13(5):734. doi:10.3390/brainsci13050734
9. Nesterowicz M, Lauko KK, Żendzian-Piotrowska M, Ładny JR, Zalewska A, Maciejczyk M. Agomelatine’s antiglycoxidative action—In vitro and in silico research and systematic literature review. Front Psychiatry. 2023;14. doi:10.3389/FPSYT.2023.1164459/FULL
10. Cao Y, Wang F, Wang Y, Long J. Agomelatine prevents macrophage infiltration and brain endothelial cell damage in a stroke mouse model. Aging. 2021;13(10):13548-13559. doi:10.18632/aging.202836
11. Lan T, Wu Y, Zhang Y, et al. Agomelatine rescues lipopolysaccharide-induced neural injury and depression-like behaviors via suppression of the Gαi-2-PKA-ASK1 signaling pathway. J Neuroinflammation. 2022;19(1):117. doi:10.1186/s12974-022-02479-x
12. Toljan S, Demarin V. Melatonin therapy in chronic pain syndrome. Rad Hrvatske akademije znanosti i umjetnosti Medicinske znanosti. 2022;58-59:82-87. doi:10.21857/m3v76t53ry
13. Rivlin AS, Tator CH. Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. Surg Neurol. 1978;10(1):38-43.
14. Kayabaş M, Makav M, Yiğit S, Aras L, Şahin L. Effect of Agomelatine on Ischemic Damage in Experimental Head Trauma Model in Rats. Turkish Journal of Veterinary Research. 2025;9(1):41-47. doi:10.47748/tjvr.1577903
15. Kigerl KA, Mostacada K, Popovich PG. Gut Microbiota Are Disease-Modifying Factors After Traumatic Spinal Cord Injury. Neurotherapeutics. 2018;15(1):60-67. doi:10.1007/s13311-017-0583-2
16. Xie C, Shen X, Xu X, et al. Astrocytic YAP Promotes the Formation of Glia Scars and Neural Regeneration after Spinal Cord Injury. The Journal of Neuroscience. 2020;40(13):2644-2662. doi:10.1523/JNEUROSCI.2229-19.2020
17. Zhang N, Yin Y, Xu SJ, Wu YP, Chen WS. Inflammation & apoptosis in spinal cord injury. Indian Journal of Medical Research. 2012;135(3). https://journals.lww.com/ijmr/fulltext/2012/35030/inflammation___apoptosis_in_spinal_cord_injury.5.aspx
18. Yu M, Wang Z, Wang D, Aierxi M, Ma Z, Wang Y. Oxidative stress following spinal cord injury: From molecular mechanisms to therapeutic targets. J Neurosci Res. 2023;101(10):1538-1554. doi:10.1002/jnr.25221
19. Ren H, Chen X, Tian M, Zhou J, Ouyang H, Zhang Z. Regulation of Inflammatory Cytokines for Spinal Cord Injury Repair Through Local Delivery of Therapeutic Agents. Advanced Science. 2018;5(11). doi:10.1002/advs.201800529
20. Ozcan M, Canpolat S, Bulmus O, et al. Agomelatine pretreatment prevents development of hyperglycemia and hypoinsulinemia in streptozotocin‐induced diabetes in mice. Fundam Clin Pharmacol. 2019;33(2):170-180. doi:10.1111/fcp.12413
21. Demirdaş A, Nazıroğlu M, Ünal GÖ. Agomelatine reduces brain, kidney and liver oxidative stress but increases plasma cytokine production in the rats with chronic mild stress-induced depression. Metab Brain Dis. 2016;31(6):1445-1453. doi:10.1007/s11011-016-9874-2
22. Gelen V, Özkanlar S, Kara A, Yeşildağ A. Citrate‐coated silver nanoparticles loaded with agomelatine provide neuronal therapy in acute cerebral ischemia/reperfusion of rats by inhibiting the oxidative stress, endoplasmic reticulum stress, and P2X7 receptor‐mediated inflammasome. Environ Toxicol. 2024;39(3):1531-1543. doi:10.1002/tox.24021
23. Yao K, Zhao Y fei, Zu H bing.
Melatonin receptor stimulation by agomelatine prevents Aβ-induced tau phosphorylation and oxidative damage in PC12 cells
. Drug Des Devel Ther. 2019;Volume 13:387-396. doi:10.2147/DDDT.S18268424. Li Q, Liu S, Zheng T, et al. Grafted human-induced pluripotent stem cells-derived oligodendrocyte progenitor cells combined with human umbilical vein endothelial cells contribute to functional recovery following spinal cord injury. Stem Cell Res Ther. 2024;15(1):35. doi:10.1186/s13287-024-03651-1
25. de Mello AH, Souza L da R, Cereja ACM, et al. Effect of subchronic administration of agomelatine on brain energy metabolism and oxidative stress parameters in rats. Psychiatry Clin Neurosci. 2016;70(4):159-166. doi:10.1111/pcn.12371
26. Dagytė G, Crescente I, Postema F, et al. Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress. Behavioural Brain Research. 2011;218(1):121-128. doi:10.1016/j.bbr.2010.11.045
27. Dagytė G, Trentani A, Postema F, et al. The Novel Antidepressant Agomelatine Normalizes Hippocampal Neuronal Activity and Promotes Neurogenesis in Chronically Stressed Rats. CNS Neurosci Ther. 2010;16(4):195-207. doi:10.1111/j.1755-5949.2009.00125.x
28. Sobrido-Cameán D, Robledo D, Sánchez L, Rodicio MC, Barreiro-Iglesias A. Serotonin inhibits axonal regeneration of identifiable descending neurons after a complete spinal cord injury in lampreys. Dis Model Mech. Published online January 1, 2019. doi:10.1242/dmm.037085
29. Saleki K, Alijanizadeh P, Javanmehr N, Rezaei N. The role of Toll‐like receptors in neuropsychiatric disorders: Immunopathology, treatment, and management. Med Res Rev. 2024;44(3):1267-1325. doi:10.1002/med.22012
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Rats
This work is licensed under a Creative Commons Attribution 4.0 International License.
